LTRN

HEALTHCARE

Lantern Pharma Inc

$2.14-0.02 (-0.93%)PRE

Live · NASDAQ · May 8, Close

AI Insight

What's Moving LTRN Today?

No stock-specific AI insight has been generated for LTRN yet. Check back soon — insights are generated from recent news analysis.

52-Week Range

$1.11$5.74

$2.14

Fundamentals

Market Cap$24M

P/E Ratio—

EPS$-1.57

Dividend Yield—

Dividend / Share—

ROE-1.2%

Profit Margin—

Debt / Equity—

Trading

Volume131K

Avg Volume (10D)—

Shares Outstanding11.3M

LTRN News

20 articles

Lantern Pharma Unveils Roadmap for withZeta.ai — Industry-First, Multi-Agentic Co-Scientist Featuring Swarm Intelligence and Computational Biology Toolkit with the Launch of ZetaSwarm™ and ZetaOmics™Yahoo Finance·May 7, 2026
Lantern Pharma’s predictBBB.ai Evolves Into a Real-Time Large Quantitative Model (LQM) for Precision Molecular Intelligence — Comprehensive Small Molecule Characterization & Development Analytics Available as a Web Service to Drug Developers GloballyYahoo Finance·Apr 29, 2026
New to The Street Broadcasts Show #746 Tonight on Bloomberg Television 6:30PM EST Featuring NRx Pharma (NASDAQ:NRXP), Performance Golf, Lost Soldier Oil & Gas, Dr. Lee Gause, and CISO GlobalYahoo Finance·Apr 25, 2026
CORRECTION: Join Lantern Pharma on April 30 for the First Public Demonstration of withZeta.ai - A Platform to Conquer Rare CancersYahoo Finance·Apr 24, 2026
Join Lantern Pharma on April 30 for the First Public Demonstration of withZeta.ai - A Platform to Conquer Rare CancersYahoo Finance·Apr 24, 2026
Lantern Pharma to Debut Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific DebutYahoo Finance·Apr 24, 2026
Emerging Data for Lantern Pharma’s Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With No Added ToxicityYahoo Finance·Apr 20, 2026
RedChip's Biotech Investor Conference Replays Now AvailableYahoo Finance·Apr 20, 2026
Lantern Pharma Launches withZeta.ai — the World’s First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22Yahoo Finance·Apr 14, 2026
Lantern Pharma Inc (LTRN) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ...Yahoo Finance·Apr 3, 2026
RedChip Showcases Public Companies Driving Biotech Innovation at April 16 Virtual Investor ConferenceYahoo Finance·Apr 2, 2026
Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare Cancers — 8:30 AM Eastern, April 9, 2026Yahoo Finance·Apr 2, 2026
Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatesYahoo Finance·Mar 30, 2026
New to The Street Broadcasts Show #740 on Bloomberg Television at 6:30 PM EST Featuring Medicus (MDCX), Acme Markets- Canton Foundation, Alpha Ton Capital (ATON), and Virtuix Holdings (NASDAQ:VTIX)Yahoo Finance·Mar 28, 2026
Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party ReportYahoo Finance·Mar 27, 2026
Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001Yahoo Finance·Mar 27, 2026
RedChip AI Investor Conference Replays Now Available Highlighting Companies Driving Innovation Across the AI EcosystemYahoo Finance·Mar 27, 2026
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ETYahoo Finance·Mar 23, 2026
New to The Street Announces Broadcast of Show #739 on Bloomberg Television Across the U.S. at 6:30 PM ESTYahoo Finance·Mar 21, 2026
RedChip Highlights Public Companies Advancing the Next Phase of AI Adoption at Virtual Investor Conference on March 19Yahoo Finance·Mar 16, 2026

All 20 articles loaded

Price Data

Open$2.12

Previous Close$2.16

Day High$2.16

Day Low$2.05

52 Week High$5.74

52 Week Low$1.11

52-Week Range

$1.11$5.74

$2.14

Fundamentals

Market Cap$24M

P/E Ratio—

EPS$-1.57

Dividend Yield—

Dividend / Share—

ROE-1.2%

Profit Margin—

Debt / Equity—

Trading

Volume131K

Avg Volume (10D)—

Shares Outstanding11.3M

About Lantern Pharma Inc

Lantern Pharma Inc., a clinical-stage biotechnology company, focuses on developing precision cancer therapies using artificial intelligence, genomics, and machine learning. The company is headquartered in Dallas, Texas.

lanternpharma.com

24 employees

Listed June 11, 2020

HEALTHCAREBIOTECHNOLOGY

Company Details

Security TypeStock

ExchangeNASDAQ

CurrencyUSD

Round Lot—

SICBIOTECHNOLOGY

CIK—

Composite FIGI—

Share Class FIGI—